BiotechTube

GCC2005 + Cyclophosphamide + Fludarabine

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lymphoma, T-Cell

Conditions

Lymphoma, T-Cell

Trial Timeline

Mar 7, 2025 → Aug 1, 2027

NCT ID
NCT06699771

About GCC2005 + Cyclophosphamide + Fludarabine

GCC2005 + Cyclophosphamide + Fludarabine is a phase 1 stage product being developed by Artiva Biotherapeutics for Lymphoma, T-Cell. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06699771. Target conditions include Lymphoma, T-Cell.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06699771Phase 1Recruiting

Competing Products

20 competing products in Lymphoma, T-Cell

See all competitors
ProductCompanyStageHype Score
AFM13AffimedPhase 2
44
Pirtobrutinib + Brexucabtagene AutoleucelEli LillyPhase 2
52
EnzastaurinEli LillyPhase 2
52
Avastin + Gemcitabine + Oxaliplatin + Pegaspargase + DexamethasoneEli LillyPhase 2
52
Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)Eli LillyPhase 2
52
VIP152 + BTKiVincerx PharmaPhase 1
25
Tomivosertib (eFT-508)eFFECTOR TherapeuticsPhase 1/2
33
Nanatinostat in combination with valganciclovirViracta TherapeuticsPhase 2
44
Sepantronium BromideCothera BiosciencePhase 2
44
Copanlisib + RituximabCelltrionPhase 2
52
Rituximab + PembrolizumabCelltrionPhase 2
52
Rituximab + Methotrexate + Cytarabine InjectionCelltrionPhase 2
52
rituximabCelltrionPhase 1
33
CT-P10 + RituxanCelltrionPhase 3
77
Rituxan + CT-P10 + Cyclophosphamide + Vincristine + PrednisoneCelltrionPhase 3
77
Rituximab, lenalidomideCelltrionPhase 2
52
Rituximab + Lenalidomide + ValemetostatDaiichi SankyoPhase 1/2
41
Valemetostat tosylateDaiichi SankyoPhase 2
52
PLX3397Daiichi SankyoPhase 2
52
Valemetostat TosylateDaiichi SankyoPhase 2
52

Other Products from Artiva Biotherapeutics

Allogeneic NK CellsPhase 2
44
AFM13 + AB-101 + Cyclophosphamide + Fludarabine + Interleukin-2Phase 2
44
AB-201 + Cyclophosphamide + FludarabinePhase 1/2
33
AB-101 + Rituximab + Interleukin-2 + Cyclophosphamide + Fludarabine + BendamustinePhase 1/2
33
AB-101 + Cyclophosphamide + Fludarabine + Rituximab + ObinutuzumabPhase 1
25